Exabis Library
Welcome to the e-CCO Library!
DOP54: Guselkumab and golimumab combination induction therapy in Ulcerative Colitis results in early local tissue healing that is sustained through guselkumab maintenance therapy
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP54: Identification and development of a 1st in class naturally-derived protein that drives mucosal healing and is orally delivered by an engineered cellular therapy targeting the gastro-intestinal tract
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP54: Integrated network analysis using patient-specific single nucleotide polymorphism profiles uncovers new pathways involved in Ulcerative Colitis pathogenesis
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP54: Integrated network analysis using patient-specific single nucleotide polymorphism profiles uncovers new pathways involved in Ulcerative Colitis pathogenesis
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP54: Real-world effectiveness of thiopurine monotherapy in Crohn’s Disease: Is there still a place for thiopurines in the biological era?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP54: Time to effect of biologics and small molecules for patients with moderately to severely active luminal Crohn's disease – a systematic review and network meta-analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP54: Time to effect of biologics and small molecules for patients with moderately to severely active luminal Crohn’s disease – a systematic review and network meta-analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP55 A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP55: ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases using whole-exome sequencing
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP55: A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in Ulcerative Colitis: Results from EVOLVE
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP55: A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in Ulcerative Colitis: Results from EVOLVE
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP55: High diagnostic accuracy of 4-probe methylation biomarkers in paediatric Inflammatory Bowel Disease by epigenome-wide analysis
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP55: Histopathological features at diagnosis to predict long-term disease course of Crohn’s Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP55: Long-term outcomes after histologic-endoscopic mucosal healing: Results from the UNIFI study in Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP55: The increasing burden of direct and indirect costs of IBD
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP55: The increasing burden of direct and indirect costs of IBD
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP55: ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases using whole-exome sequencing
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extension
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP56: Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP56: Fibrosis-related transcriptome unveils a distinctive matrix remodelling pattern in penetrating but not in stricturing ileal Crohn's Disease
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM